Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash & Equivalents (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Cash & Equivalents data on record, last reported at $149.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 11.34% year-over-year to $149.5 million; the TTM value through Sep 2025 reached $149.5 million, down 11.34%, while the annual FY2024 figure was $215.4 million, 164.91% up from the prior year.
  • Cash & Equivalents reached $149.5 million in Q3 2025 per PRAX's latest filing, down from $157.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $215.4 million in Q4 2024 and bottomed at $56.0 million in Q2 2022.
  • Average Cash & Equivalents over 4 years is $119.9 million, with a median of $124.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 164.91% in 2024, then fell 11.34% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $61.6 million in 2022, then skyrocketed by 31.95% to $81.3 million in 2023, then surged by 164.91% to $215.4 million in 2024, then plummeted by 30.57% to $149.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $149.5 million in Q3 2025, $157.4 million in Q2 2025, and $165.6 million in Q1 2025.